- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01494337
Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)
Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction from BPH seen through the outpatient clinic in the urology department will be assessed to see if the patient satisfies all inclusion and exclusion criteria. Patients who are meeting these criteria will be asked to participate in this randomized comparison study. If they agree they will be provided with an informed consent form which they can take home with them. The randomization process will be performed using computer-generated simple random tables in a 1:1 ratio. Study participants will be enrolled randomized, and the appropriate surgery scheduled. Procedures will be performed on an outpatient basis whenever possible.
All surgeries will be performed under a spinal or general anaesthesia. In case of coexisting vesical stone, Holmium laser cystolithotripsy will be done first regardless the type of next procedure for the prostate. Both HOLEP and greenLight (XPS) laser vaporization of the prostate begins with the insertion of a resectoscope transurethrally. Examination of the lower urinary tract is performed and holmium laser fiber is used to enucleate (HOLEP) or to vaporize [greenLight (XPS)] the obstructing prostatic tissue using the Moxy fibre until the surgical capsule is reached. After treatment, the prostatic fossa will be examined for hemostasis and if adequate, a 22 french Foley catheter will be inserted. Patients will then be sent to the post-anaesthetic recovery room.
Once awake, the patient could have the catheter removed with a voiding trial if the urine is judged to be sufficiently clear and the surgeon is comfortable about early catheter removal. Those patients able to void will be sent home without catheter. Those patients unable to void or the surgeon decides to keep the catheter for 24 hours will be either sent home with a catheter to be removed the next day or hospitalized overnight.
Finally, those patients with multiple medical problems or with postoperative bleeding requiring bladder irrigation will be kept overnight with a trial of voiding attempted the next morning if the urine is clear.
Intraoperative and early postoperative parameters of interest will be recorded and compared between groups. These parameters include the total procedure time, total laser energy used, cost of disposables including the number of laser fibers per case, number of bags of irrigant per case, urethral catheterization time, length of hospital stay, subjective assessment of hemostasis during each laser procedure, objective assessment of changes in serum electrolytes and hematocrit and thorough recording of all complications.
Patients will be seen in follow-up at 2 weeks, 1, 3, 6, and 12 months. The parameters to be assessed at each time point are listed below. As can be seen from the table, the most important parameters will be changes in voiding symptoms and uroflowmetry over time. Some validated questionnaires will be utilized to assess the patients' sexual function both at base line and at different follow-up visits. Different aspects of the sexual function will be analysed, partner's feedback will be addressed by a special questionnaire.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Royal Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to give informed consent.
- Lower urinary symptoms (LUTS) secondary to bladder outlet obstruction from BPH.
- Failed medical treatment of BPH.
- International prostate symptom scores (IPSS) > 15.
- Peak urinary flow rate (Qmax) < 15 ml/sec.
- Preoperative TRUS (transrectal ultrasound) size of the gland (from 40 to 150 cc).
- Patients in retention secondary to BPH (with cystometrogram (CMG) confirming adequate detrusor pressure if the bladder capacity at time of catheterization is in excess of 1000 ml).
Exclusion Criteria:
- Inability to give informed consent.
- Patient who have a neurological disorder which might affect bladder function as cerebrovascular stroke, Parkinson disease.
- Active urinary tract infection.
- Presence of active bladder cancer (within the last 2 years).
- Known cancer prostate patients will be excluded preoperatively on the basis of digital rectal examination, prostate specific antigen level, and TRUS imaging followed by prostate biopsies if necessary.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: HOLEP
HOLEP In the first arm, holmium laser enucleation of the prostate will be done
|
USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
Other Names:
|
|
Active Comparator: PVEP/XPS
PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
|
Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in urine flow parameters
Time Frame: one, 4 and 12 months postoperative
|
change in urine flow parameters; IPSS= international prostate symptom score QOL= quality of life score PVR= post voiding residual urine Q-MAX= maximal flow rate
|
one, 4 and 12 months postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TIME TO CATHETER REMOVAL, HOSPITAL STAY
Time Frame: 1 day post operative
|
At first postoperative day; the catheter will be removed for trial voiding Patient will be discharged from the hospital as soon as possible (same day or once urine color is normalized)
|
1 day post operative
|
|
the need for redo surgery
Time Frame: 1 year
|
The need for re-operation in the fist year will be assessed
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mostafa M Elhilali, Professor, McGill University Health Centre/Research Institute of the McGill University Health Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-171-SDR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostate Hyperplasia
-
Yonsei UniversityCompletedBPH( Benign Prostate Hyperplasia) | TURP(Transurethral Resection of Prostate)Korea, Republic of
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Tribhuvan University Teaching Hospital, Institute...CompletedBacteriuria in Symptomatic Benign Prostate Hyperplasia | Antibiotic Susceptibility in Symptomatic Benign Prostate Hyperplasia | Treatment Response to Antibiotics in Symptomatic Benign Prostate HyperplasiaNepal
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
Liselot RibbertMaastricht University Medical Center; Catharina Ziekenhuis Eindhoven; Spaarne... and other collaboratorsRecruitingBenign Prostate Hyperplasia | Benign Prostate Obstruction | Acute Urinary Retention | Benign Prostate Hypertrophy(BPH)Netherlands
-
University of ManitobaNot yet recruitingBenign Prostate Hypertrophy(BPH)Canada
-
St. Luke's Medical Center, PhilippinesCompletedBenign Prostatic Hyperplasia | Prostate Cancer | ProstatitisPhilippines
-
Medi-Tate Ltd.CompletedBenign Prostate HyperplasiaUnited States, Canada
Clinical Trials on HOLEP
-
GCS Ramsay Santé pour l'Enseignement et la RechercheTerminated
-
Thunder Bay Regional Health Research InstituteNorthern Ontario School of MedicineActive, not recruitingLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaCanada
-
University of Kansas Medical CenterCompleted
-
Mansoura UniversityCompleted
-
Northwestern UniversityRecruitingUrologic Diseases | Prostate ObstructionUnited States
-
Ankara City Hospital BilkentNot yet recruitingDriving Pressure | Lung Protective Ventilation | Holmium Laser Enucleation of the ProstateTurkey (Türkiye)
-
Olympus Surgical Technologies EuropeTerminatedBenign Prostatic HypertrophyChina
-
Ain Shams UniversityCompletedBenign Prostatic HyperplasiaEgypt
-
University of BariGaetano de Rienzo; Pasquale Ditonno; Francesco Di Modugno; Michele Battaglia; Giuseppe... and other collaboratorsUnknownBenign Prostatic Hyperplasia (BPH)Italy
-
Mansoura UniversityActive, not recruitingBenign Prostate Hyperplasia | Bladder Outlet ObstructionEgypt